ArticleScientific reports2026
High expression of STAT3 and PD-L1 predicts poor prognosis for laryngeal squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neupogen/MSCs conditioned media inhibit HEp-2 laryngeal cancer cells proliferation by down regulating miRNA 21expression and ROS production.Molecular biology reports · 2026Article
- YWHAG overexpression correlates with an immune-desert microenvironment and poor prognosis in laryngeal squamous cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Laryngeal squamous cell carcinoma (LSCC) ranks among the most prevalent malignant tumors in the head and neck region. Signal transducer and activator of transcription 3 (STAT3) belongs to the family of cytoplasmic latent transcription factors, which has been discovered to be activated in various human cancers and is linked to cancer progression, lymph node metastasis, and unfavorable prognosis. Programmed cell death 1/ programmed cell death ligand 1 (PD-1/PD-L1) has a significant role in the immunosuppressive processes of numerous cancers. However, the specific roles of STAT3 and PD-L1 in LSCC remain unclear. Single sample GSEA was used to explore the link between STAT3 and immune cell infiltration. The Cancer Genome Atlas (TCGA) database revealed the expression levels of STAT3 and PD-L1 and their correlation on mRNA level in patients with LSCC. The expression of STAT3 and PD-L1 proteins was analyzed using immunohistochemistry (IHC). STAT3 and PD-L1 expression were significantly elevated in LSCC tumors. The overall survival rates were notably higher for LSCC patients with low levels of STAT3 and PD-L1 expression than for those with high levels (both P < 0.05). Increased levels of the STAT3, PD-L1 and in combination were positively linked to the pathological differentiation and lymph node metastasis status in patients with LSCC(all P < 0.05). Compared to normal tissue, LSCC exhibited significantly elevated mRNA levels of STAT3 and PD-L1, with both STAT3 and PD-L1 demonstrating a notable increase in expression in LSCC samples at the mRNA and protein levels compared to non-cancerous tissue. Increased STAT3 and PD-L1 may function as promising biomarkers indicating poor prognosis in patients who have undergone surgical resection for LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.